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Context: Osteoporosis has a significant genetic component. The aro-
matase-dependent conversion of androgenic precursors is the main
source of estrogens in postmenopausal women.
Objective: The objective of the investigation was to study the rela-
tionship of a set of single nucleotide polymorphisms (SNPs) of the
aromatase gene with osteoporosis and determine their functional
influence on gene transcription.
Design, Participants, and Methods: This was a case-control study
including 135 women with vertebral fractures due to postmenopausal
osteoporosis and 312 controls. Alleles at four SNPs situated between
exons I.2 and 3 were determined by Taqman assays. Total aromatase
RNA and differential allelic-specific expression were studied by RT-
real time PCR in adipose tissue samples taken from 50 individuals.
Results: The SNPs studied were in strong linkage disequilibrium.
A common haplotype, present in about half of the population, was
identified as being associated with an increased risk of fractures
(odds ratio 1.8, 95% confidence interval 1.2–2.8, P  0.006). There
was evidence of differential allelic expression. In heterozygous
individuals, transcripts bearing T alleles at rs700518 SNP (which
were included in the risk haplotype) were less abundant than those
with the alternative C alleles (P  0.001). Total aromatase ex-
pression was four times lower in fat samples from individuals who
were homozygotes for the unfavorable alleles than in the opposite
homozygotes (P  0.007).
Conclusions: A common haplotype of aromatase associated with
gene expression is also associated with the risk of osteoporotic
vertebral fractures in postmenopausal women. These data are in
line with the hypothesis that the aromatase-dependent synthesis
of estrogens plays an important role in bone homeostasis in post-
menopausal women. (J Clin Endocrinol Metab 92: 660–665,
2007)
ESTROGENS PLAY A CRITICAL role in bone homeosta-sis, and the decline in estrogen availability after the
menopause is a central factor in the development of post-
menopausal osteoporosis (1). However, genetic factors are
known to have an important influence on bone mass and
osteoporosis risk (2–4). Given the role of estrogens in bone
homeostasis, genes related to estrogen metabolism are likely
candidates to contribute to such hereditary influence.
The main source of estrogens in postmenopausal women
is the aromatization of androgenic precursors, a reaction
catalyzed by aromatase, the product of the CYP19A1 gene
(5). In humans the gene is expressed in not only the gonads
but also other tissues, including the adipose tissue and bone.
The influence of aromatase-derived estrogens on the skeleton
is revealed by the reduction of bone mineral density (BMD)
in postmenopausal women treated with aromatase inhibitors
(6).
The CYP19A1 gene is located on chromosome 15q21 and
spans about 120 kb. It has a complex structure, with a 30-kb
coding region and a long 5 region, spanning about 90 kb.
This 5 region contains regulatory sequences and several
variants of the first exon, whose transcription is driven by
different tissue-specific promoters. These alternative forms
of the first exon are transcribed and, after RNA splicing,
joined onto a common splice acceptor site in exon 2, imme-
diately upstream of the coding region (7). Thus, the mature
mRNA contains a variable nontranslated first exon and a
common set of exons 2–10 coding for the amino acid se-
quence of aromatase. Several investigators have reported an
association between some common polymorphisms of the
aromatase gene and BMD (8, 9). In a previous study, we
reported that polymorphisms situated between exon I.2 and
the coding region showed a closer association to BMD than
those situated in regions further 5 upstream (10). Therefore,
in this study we genotyped other polymorphisms in that
region to identify combination haplotypes associated with
osteoporotic fractures and explored their functional rele-
vance by determining their influence on gene transcription.
Subjects and Methods
Study subjects
We studied two groups of postmenopausal women aged over 50 yr.
The fracture group included 135 women with postmenopausal osteo-
porosis and nontraumatic vertebral fractures confirmed by lateral x-rays
of the spine showing a decrease in vertebral height of at least 20%. The
control group included 312 control women recruited by voice and writ-
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ten announcements from various sources to prevent a preferential se-
lection bias (hospital workers, civic associations, religious groups, and
geriatric residences). All were living in Cantabria, a region in Northern
Spain with a population of 530,000. All subjects were interviewed by one
of the investigators to check the absence of exclusion criteria. Subjects
taking bisphosphonates, corticosteroids, antiepileptics, thiazides, estro-
gens, or other drugs known to modify bone mass as well as those with
past or present diseases known to affect bone metabolism, poor mental
or physical performance status, or non-Spanish ancestry were excluded.
Causes of secondary osteoporosis were excluded by clinical examination
and laboratory tests (including complete blood count, erythrocyte sed-
imentation rate, serum biochemical profile, protein electrophoresis, thy-
roid hormones, and PTH). Calcium intake from dairy products was
estimated by a questionnaire (10). Present physical activity was graded
semiquantitatively by the number of weekly sessions of weight-bearing
exercise. Alcohol intake was defined as a daily intake of more than 10 g.
Women were regarded as smokers if they had a present or past history
of smoking at least five cigarettes per day for a minimum of 5 yr. Age
at menarche and menopause was established by recalling the first and
last menstruation, respectively. The study protocol was approved by the
Institutional Committee of Ethics in Clinical Research, and informed
consent was obtained from study subjects.
Genotyping
Previous work suggested an association of some single nucleotide
polymorphisms (SNPs) situated around the translation start site of
CYP19A1 with bone mass (10). Therefore, we decided to study other
SNPs in that region. These included: 1) rs1062033, a C/G polymorphism
situated in exon I.2 (at position 49,335,230; human genome map build
36.1); 2) rs767199, an A/G polymorphism located between alternative
exons I.2 and I.6 (at position 49,327,679); 3) rs4775936, a C/T SNP located
in the vicinity of exon I.6 (at position 49,323,314); and 4) rs700518, a
synonymous C/T SNP in exon 3 (at position 49,316,404). They were
selected after exploring public databases (National Center for Biotech-
nology Information, Hapmap, Celera) because they could be analyzed
by readily available Taqman assays, had balanced allelic frequencies,
and some other interesting characteristics: previously published asso-
ciation with bone mass [rs1062033 and rs4775936 (11, 12)]; exonic loca-
tion that allowed it to be used as an allele expression marker (rs700518);
or an intermediate location between other distant markers (rs767199).
Linkage disequilibrium was not considered a priori. The two flanking
SNPs were used in gene expression studies.
Genomic DNA was obtained from the peripheral blood using a com-
mercial kit, following the manufacturer’s instructions (QIAGEN,
Hilden, Germany). Genotyping was performed using allele-specific Taq-
man probes labeled with VIC and FAM. Primers and probes were
designed by the manufacturer with Primer Express software (Taqman
Assays-on-Demand, Applied Biosystems, Foster City, CA). Amplifica-
tion reactions were performed in a 5-l volume in optical 96-well plates,
with 1 l DNA (10–20 ng), 2.5 l universal PCR master mix (Applied
Biosystems), and 0.25 l assay mix with the specific primers and probes.
After amplification, the fluorescence was read in an ABI7300 sequence
detector (Applied Biosystems). About 5% of the results were ambiguous
and samples had to be retyped. Random samples were analyzed twice
to check for consistency of results. DNA analysis was performed blindly
from other results. The existence of potential binding sites within the
regions studied was explored by searching the TRANSFAC database
with P-Match software (www.gene-regulation.com).
Aromatase gene expression in adipose tissue
Gene expression was analyzed by real-time RT-PCR. Subcutaneous
fat samples were obtained during abdominal surgical procedures, snap
frozen in liquid nitrogen, and stored at 70 C. Total RNA was isolated
by using a commercial kit (lipid minikit, QIAGEN), following the man-
ufacturer’s instructions, after homogenizing samples (100 mg) with a
ball mill (Sartorius, Goettingen, Germany). Aliquots of RNA (1–4 g)
were reverse transcribed with the Superscript III kit (Invitrogen, Paisley,
UK), using random hexamers as primers. In negative control reactions,
reverse transcriptase was omitted. After RT-PCR, aromatase gene ex-
pression was determined by real-time PCR in an ABI7300 apparatus
(Applied Biosystems). The reactions were performed in triplicate in
96-well plates containing aliquots of the cDNA obtained by reverse
transcription (RT), 5 l of universal PCR master mix, and primers and
probe complementary to an exonic boundary in the aromatase common
transcript region (Taqman gene expression assays, Applied Biosystems).
The cycle threshold (Ct) was determined. This represents the cycle at
which a significant increase in fluorescence is first detected and is in-
versely related to the amount of target cDNA in the starting material. The
results were normalized to TATA box binding protein (TBP) expression
analyzed in the same reaction plate to take into account possible be-
tween-sample differences in RNA amount and quality as well as vari-
ability in the efficiency of RT. Control samples of reverse-transcribed
reference human RNA (Stratagene, La Jolla, CA) were also included. The
relative RNA levels were calculated using the formula 2Ct1  Ct2, where
Ct1 is the difference between the control cDNA Ct and the sample
cDNA Ct when the target gene (aromatase) is amplified, and Ct2 is the
difference between control cDNA Ct and the sample cDNA Ct when the
control gene (TBP) is amplified.
Differential allelic expression
Differential allelic expression was studied in a series of fat samples
from individuals who were heterozygous for the rs700518 polymor-
phism (situated in the coding region of the gene) by a modification of
the RT-coupled 5 nuclease assay-based procedure (13, 14). RNA was
extracted from fat samples as described above and residual DNA was
removed by treating samples with DNase. After RT as described, the
expression level of each allele was studied by real-time PCR with uni-
versal PCR master mix and the primers and allele-specific probes used
for genotyping. Amplification of each allele was determined by moni-
toring the fluorescence of FAM and VIC-labeled probes. The Ct of each
allele was determined. When the expression from one allele is dominant,
amplification of the transcript from that allele will reach the threshold
at an earlier cycle, thus having a smaller Ct. The difference in Ct (Ct)
is a measure of differential expression between the alleles. In general, the
expression of one allele to the other is in a ratio 1:2 Ct. Although cycle
thresholds are directly related to the amount of specific cDNA present
in the sample, the allele-specific Ct may also be influenced by other
factors, such as the different fluorescence signal efficiency of FAM and
VIC labels. Therefore, a standard curve was constructed with serial
dilutions of two homozygous genomic DNA mixed in different pro-
portions. The regression curve fitted an exponential function (r2  0.98)
that was used to calculate the expression ratio from each allele from the
observed Ct with the formula: allele ratio  3.592  e0.237 Ct.
The ratio of allele-specific cDNA from reverse-transcribed RNA iso-
lated from adipose tissue samples was compared with the ratio of
allele-specific genomic DNA isolated from the blood cells of heterozy-
gous individuals (which is expected to equal 1).
Statistical analyses
Hardy-Weinberg equilibrium was tested with HWSIM software
(http://krunch.med.yale.edu/hwsim/hwsim.doc). Linkage disequilib-
rium between different loci was estimated by the normalized distances
and correlation coefficients, estimated with Haploview (www.broad.
mit.edu/mpg/haploview). Haplotype reconstruction was performed
with two different software packages, Phase v2 (15) (http://www.stat.
washington.edu/stephens/software.html) and Chaplin (16) (http://
www.genetics.emory.edu/labs/epstein/software/), and haplotype fre-
quencies were computed. Very similar results were obtained with both
programs. Differences in the global distribution of haplotypes between
patients and controls were first assessed with a PAC-likelihood permu-
tation test implemented in Phase. Then the association of frequent (5%)
individual haplotypes with vertebral fractures was estimated with the
Wald test, and different models were compared with the Akaike infor-
mation criterion (AIC), a combined index of model prediction ability and
simplicity, by using Chaplin software. Finally, haplotype-associated risk
of fracture was estimated by the odds ratio derived from logistic re-
gression analysis with SPSS software (SPSS Inc., Chicago, IL). The non-
parametric Jonckheere-Terpstra test for ordered categories was used to
analyze the differences in aromatase gene expression between subjects
with different genotypes.
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Results
Haplotypes and fractures
The characteristics of the groups are shown in Table 1.
Control women were slightly younger, taller, and more
likely to exercise than women with fractures. Allele frequen-
cies are shown in Table 2. There was no evidence for depar-
ture from Hardy-Weinberg equilibrium proportions.
The four SNPs studied were in strong linkage disequilib-
rium, with normalized distance values between 0.89
(rs700518-rs1062033 pair) and 0.97 (rs4775936-rs1062033
pair) (all P  0.001). The corresponding correlation coeffi-
cient varied between 0.66 and 0.87. Thus, only 15 of the 81
possible haplotypes were observed, and the majority of sub-
jects had one of two discordant haplotypes that together
comprised 89% of the population. The haplotype distribution
in the fracture and control groups is shown in Fig. 1. There
was a statistically significant difference in the overall hap-
lotype frequency distribution in both groups (P  0.01).
Regarding the two most common haplotypes, which had
opposite sequences, haplotype 1 (TCGC) was overrepre-
sented in fracture patients: 55.5 vs. 47.2% in controls. On the
contrary, haplotype 2 (CTAG) was less frequent in fracture
patients than controls: 34.5 vs. 39.2%. Screening of the asso-
ciation of individual haplotypes with fracture status using
different genetic models revealed that only haplotype 1 was
significantly associated with fractures, best fitting a recessive
model (beta  1,65, AIC  1638, P  0.016 in a recessive
model; beta  1.34, AIC  1639, P  0.041 in a multiplicative
model). According to their AIC, joint models including sev-
eral haplotypes did not show a better performance than
single haplotype models. The presence of two copies of hap-
lotype 1 was significantly associated with osteoporotic frac-
tures, with an unadjusted odds ratio of 1.8 (95% confidence
interval 1.2–2.8; P  0.006; Table 3), in comparison with
women with one or no copies of the haplotype. Similar re-
sults were found in multiple logistic regression models in-
cluding possible confounding factors such as age and weight
(odds ratio 1.8; confidence interval 1.2–2.9; P  0.010).
Polymorphisms and aromatase gene expression
Expression of the aromatase gene was studied in 50 indi-
viduals who were taken to surgery due to abdominal prob-
lems (usually gastrointestinal cancer, cholelithiasis, or her-
nia). RNA levels were similar in both sexes (P  0.60) and
were not related to the neoplastic or benign nature of the
underlying disease (P  0.89). Haplotype 1, which was
shown to be associated with osteoporotic fractures, included
a C allele at the rs1062033 locus. Individuals bearing such C
alleles showed lower levels of aromatase gene expression
than those with the alternative G allele, as revealed by the
smaller levels of RNA shown in Fig. 2 (P  0.007). Aromatase
RNA levels were about four times higher in samples from
individuals who were homozygotes for the G allele than in
homozygotes for the C allele. Similar differences were ob-
served when subjects were classified according to rs700518
alleles (P  0.012).
Haplotype 1 included a T allele at rs700518 locus, which
is located in the common coding region of the aromatase
gene. The analysis of the allele-specific expression in a group
of unselected heterozygous individuals (n  10) for this locus
revealed that T alleles were underexpressed in comparison
with C alleles. Thus, the average ratio of C-containing tran-
scripts to T-containing transcripts was 1.97 	 0.47 (ranging
from 1.39 to 2.67; Fig. 3), which was significantly different
from 1 and from the value of 1.01 	 0.16 found in samples
of genomic DNA (P  0.001).
Discussion
This study shows that a common haplotype of the aro-
matase gene, present in about half of the population, is as-
sociated with osteoporosis. The haplotype appears to behave
as recessive; thus, the group of postmenopausal women bear-
ing two copies of the haplotype, roughly one fourth of the
population, appeared to have an increased risk of osteopo-




(n  135) P
Age (yr) 67 	 8 70 	 7 0.001
Height (cm) 155 	 6 153 	 6 0.001
Weight (kg) 66 	 10 64 	 10 0.06
Body mass index (kg/m2) 27.4 	 14.1 27.3 	 3.8 ns
Age at menarche (yr) 14 	 2 14 	 2 ns
Age at menopause (yr) 50 	 5 49 	 5 ns
Duration of menopause (yr) 17 	 10 21 	 9 0.001
Calcium intake (mg/d) 688 	 378 632 	 357 0.15
Smokers (%) 12.0 10.7 ns
Alcohol (%) 10.1 3.3 0.04
Weight-bearing exercise (%) 32.6 18.4 0.01
ns, Not significant.
TABLE 2. Allele frequencies in fracture patients and controls
SNP Allele All Control Fracture P
rs700518 C 0.459 0.477 0.418
T 0.541 0.523 0.582 0.10
rs4775936 C 0.575 0.555 0.621
T 0.425 0.445 0.379 0.07
rs767199 A 0.466 0.489 0.415
G 0.534 0.511 0.585 0.04
rs1062033 C 0.588 0.572 0.625
G 0.412 0.428 0.375 0.13










FIG. 1. Haplotype distribution in fracture patients and controls (only
haplotypes with a frequency above 1% are shown).
662 J Clin Endocrinol Metab, February 2007, 92(2):660–665 Riancho et al. • Aromatase Haplotypes and Osteoporosis
rotic fractures (odds ratio slightly less than 2). These results
are in line with previous data in a partially overlapping
population, showing an association between common vari-
ants of the aromatase gene (as the C alleles at rs1062033) and
osteoporosis (10). Other investigators have also reported an
association between aromatase polymorphisms and BMD (8,
9, 12, 17).
The critical role of estrogens in bone homeostasis is widely
recognized (1), and one of its consequences is the loss of bone
occurring after the menopause, when the gonadal function
ceases. However, despite the negative results of some studies
(18), most investigators have found a positive relationship
between free estradiol and BMD in postmenopausal women
as well as an increased fracture risk in women with the lowest
serum levels of estradiol (19–23). Therefore, available evi-
dence indicates that residual estrogen activity continues to
play a role in bone metabolism after the menopause.
The aromatization of androgenic precursors is the main
source of estrogens in men and in women after the meno-
pause. A variety of human tissues have been shown to ex-
press the aromatase gene. Apart from the gonads, aromatase
activity and/or RNA transcripts have been detected in mus-
cle, fat, bone, nervous tissue, and several tumors (24). The
adipose tissue is usually regarded as a major source of es-
trogens after the menopause. In fact, serum estradiol levels
correlate with fat mass in postmenopausal women, and there
is an inverse relationship between body weight and osteo-
porosis risk (25, 26). Therefore, although multiple humoral
and physical mechanisms may be involved in the association
between body mass and bone mass, it seems likely that the
aromatase-derived production of estradiol in the adipose
tissue helps to ameliorate the tendency to lose bone after the
menopause. This does not exclude a role of locally produced
estradiol at the bone level. Bone cells express a number of
enzymes involved in steroid metabolism, including aro-
matase (27–29). Therefore, estradiol may also have a local
effect in the bone tissue, paracrine or even autocrine, as
shown in other tissues (5, 30).
There is wide evidence that aromatase activity influences
bone homeostasis. Mice not expressing aromatase have a
decreased bone mass (31, 32). In humans, a few patients with
loss-of-function mutations of the aromatase gene resulting in
profound skeletal abnormalities have been described (33).
The pharmacological inhibition of aromatase is also associ-
ated with a decrease in BMD and an increased risk of frac-
tures (6, 34).
Given the complex nature of osteoporosis, apart from cases
of rare mutations, it seems unlikely for a single gene to play
a quantitatively large role in determining bone mass. Indeed,
in most association studies candidate genes only explain a
small fraction of the total BMD variance, usually about 1–3%.
However, the overall importance of genetic factors is beyond
doubt. It has been suggested that heredity may explain be-
tween 40 and 80% of BMD variance and about 30% of fracture
risk (2, 3, 35). Our data and those of the previously published
studies mentioned above point toward aromatase as a likely
candidate gene contributing to determine, in part, osteopo-
rosis risk.
Genetic association studies may be biased by a number of
factors, including population stratification. Although diffi-
cult to exclude completely, we tried to limit this potential bias
by studying cases and controls from a limited geographical
area. More importantly, we showed that the polymorphisms
defining the osteoporosis-associated haplotype are associ-
ated with differences in aromatase gene expression. Thus,
although the SNPs we studied do not induce changes in the
amino acid sequence of aromatase, they are associated with
functional differences at the genomic level.
Allele-specific expression differences can be identified by
comparing the relative levels of exonic SNP alleles in RNA
samples from heterozygous subjects. Within an individual
RNA sample, alleles are exposed to the same cellular envi-















FIG. 2. Aromatase gene expression in adipose tissue samples, ac-
cording to genotype (alleles at the rs1062033 locus). Results represent
the amount of aromatase RNA, corrected for the amount of TBP RNA,





















FIG. 3. Allele-specific expression. Aromatase gene transcripts bear-
ing a C allele or T allele at locus rs700518 were measured by real-time
RT-PCR with allele-specific probes. The ratio of C to T alleles is
shown. The results obtained when the same PCR procedure was
applied to CT heterozygous genomic DNA samples are also shown for
comparison purposes.
TABLE 3. Distribution of haplotype 1 in fracture patients
and controls
Group All Homozygotes Heterozygotes Noncarriers
Fracture 135 (100) 48 (35.6) 57 (42.2) 30 (22.2)
Control 312 (100) 72 (23.1) 162 (51.9) 78 (25.0)
Data represent number of patients (percentage).
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regulatory polymorphisms situated within the same chro-
mosomal region. When allelic expression differences are
strongly influenced by transregulatory sequences, one ex-
onic SNP allele will be expressed at a higher level in some
heterozygous individuals, whereas the other allele will be
preferentially expressed in different individuals. However,
when allelic expression differences arise from a cis-regula-
tory polymorphism in strong linkage disequilibrium with a
coding SNP, the same exonic SNP will tend to be expressed
at a higher level in all heterozygous individuals (36). This
phenomenon has been reported to occur in about one fifth to
one third of human genes (37, 38). In the present study, we
found that T alleles at the exonic locus rs700518, present in
the osteoporosis-associated haplotype, are underexpressed
in comparison with C alleles. This was a consistent finding,
and the average allele C to allele T ratio was about 2, similar
to the ratio found in studies of other genes showing differ-
ential allelic expression (13, 14, 38).
The identification of functional variations is central to the
elucidation of the genetic component of complex diseases.
Most functional studies of potential regulatory SNPs are
based on in vitro techniques such as transient transfection
experiments with allele-specific constructs. Although infor-
mative, the results of those experiments may sometimes be
difficult to interpret, especially in large genes with a complex
structure, due to the limited size of the cloned regions and
the fact that they are studied outside their normal chromo-
somal environment. In this context, direct assessment of the
relative abundance of allelic transcripts may be preferable to
investigating allele-specific expression differences in the nor-
mal chromosomal context (38). This methodology allowed us
to identify some allelic variants of the aromatase gene with
functional consequences. The polymorphisms were associ-
ated with differences in gene expression, as demonstrated by
the marked differences in the levels of SNP-specific alleles in
samples from heterozygous individuals and the differences
in the amount of total aromatase RNA between individuals
with different genotypes. Interestingly enough, those poly-
morphisms associated with a lower level of gene expression
were also associated with an increased risk of vertebral
fractures.
However, despite this association we cannot establish
which SNP is actually responsible for the differences in gene
transcription. Searching the TRANSFAC database of tran-
scription factor binding sites by using an adipocyte-specific
profile revealed potential binding sites for transcription fac-
tors such as specificity protein-1 (Sp1) and CCAAT/enhanc-
er-binding protein (C/EBP) in the vicinity of the loci
rs1062033 and rs767199. Those factors have been shown to
modulate aromatase gene expression in some tissues (39, 40).
However, it is unclear to us whether those potential binding
sites are actually functional.
In fact, the active polymorphism could be one of those
studied here or another unidentified polymorphism in link-
age disequilibrium with them. We did not use a map-based
or tagging approach but a sequence-based approach to select
the SNPs to study. An a posteriori search of the HapMap
database suggests that CYP19A1 gene may have seven hap-
lotype blocks, with rs1062033 sitting in block 3 and the three
other SNPs in block 2. Further studies analyzing a larger
number of SNPs distributed throughout the gene are needed
to clearly identify which one of those polymorphisms, or
others in linkage disequilibrium with them, is actually re-
sponsible for the differences in aromatase gene expression.
In conclusion, we have identified a set of SNPs in the
aromatase gene that are associated with differences in gene
expression and are in strong linkage disequilibrium, result-
ing in a common haplotype that is associated with the risk
of osteoporotic fractures. These data give further support to
the hypothesis that aromatase-derived estrogens play a role
in bone homeostasis in postmenopausal women. Pending
confirmation in other population groups, they also raise the
possibility of using these gene variants as potential tools to
identify women at higher risk of osteoporosis who could
become a special target population for preventive strategies.
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